Invitrogen

Phospho-GSK3 alpha/beta (Tyr279, Tyr216) Polyclonal Antibody

Phospho-GSK3 alpha/beta (Tyr279, Tyr216) Antibody in Western Blot (WB)

FIGURE: 1 / 1

Phospho-GSK3 alpha/beta (Tyr279, Tyr216) Antibody (OPA1-03083) in WB

Up-regulation and Antibody-Peptide Competition: Peptide Competition. Extracts of 3T3L1 cells stimulated with 100 nM insulin for 10 minutes were resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF. The membrane was blocked with a 5% BSA-TBST buffer for one hour at room temperature and either left untreated (1-4) or treated with lambda phosphatase (5), and then incubated with the GSK-3a (pY... View More

Product Image Gallery

Product Details

OPA1-03083

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-Dependent

View 5 publications 5 publications

Product Specifications

Published species

Human, Mouse

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Synthetic phosphopeptide derived from regions of human GSK3alpha/beta that contain tyrosine 279/216.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Storage conditions

-20°C, Avoid Freeze/Thaw Cycles

Shipping conditions

Wet ice

AB_325633

Product Specific Information

OPA1-03083 detects the alpha and beta isoforms of phospho-GSK3 from human and mouse tissues. This antibody is expected to cross-react with rat, frog, and zebra fish GSK-3 due to 100% sequence homology.

OPA1-03083 has been successfully used in Western blot procedures. By Western blot, this antibody detects an ~51 kDa protein and an ~47 kDa protein from stimulated 3T3-L1 cells representing tyrosine 279 phosphorylated GSK3alpha and tyrosine 216 phosphorylated GSK3beta, respectively. Positive control: serum starved mouse 3T3-L1 cells +/- insulin (100 nM, 10 minutes), or background extracts +/- human recombinant GSK-3â.

OPA1-03083 immunizing phosphopeptide was derived from a regions of human GSK3alpha/beta that contain tyrosine 279/216.

Target Information

Glycogen synthase kinase-3 (GSK3) is a protein kinase that was originally identified as a regulator of glycogen synthase, a key enzyme in glycogen metabolism. Since then, it has been shown to be involved in the regulation of a diverse array of cellular functions, including protein synthesis, cell proliferation, cell differentiation, microtubule assembly/disassembly, and apoptosis. GSK3's substrate specificity is unique in that phosphorylation of the substrate only occurs if a phosphoserine or phosphotyrosine is present - four residues C-terminal to the site of GSK phosphorylation. There exists two isoforms of GSK3, GSK3 alpha and GSK3 beta, and they are strictly regulated via phosphorylation. Phosphorylation of GSK3 beta on Ser9 (Ser21 in GSK3alpha) by protein kinase B (PKB) causes its inactivation and is the primary mechanism responsible for growth factor inhibition of this kinase. Activation of GSK3 beta is dependent upon the phosphorylation of Tyr216 (Tyr279 in GSK3 alpha). Upon activation, it has been shown to phosphorylate a number of different cellular proteins, including p53, c-Myc, c-Jun, heat shock factor-1 (HSF-1), and cyclin D1. GSK3 beta also has been shown to phosphorylate aberrant sites on the microtubule associated protein tau, which is critical for the progression of Alzheimer's disease.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy.

Cancer discovery

Hinze L,Labrosse R,Degar J,Han T,Schatoff EM,Schreek S,Karim S,McGuckin C,Sacher JR,Wagner F,Stanulla M,Yuan C,Sicinska E,Giannakis M,Ng K,Dow LE,Gutierrez A

OPA1-03083 was used in Western Blotting to demonstrate that WNT-induced therapeutic vulnerabilities can be exploited for colorectal cancer therapy.

Sun Nov 01 00:00:00 UTC 2020

Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias.

Cancer cell

Hinze L,Pfirrmann M,Karim S,Degar J,McGuckin C,Vinjamur D,Sacher J,Stevenson KE,Neuberg DS,Orellana E,Stanulla M,Gregory RI,Bauer DE,Wagner FF,Stegmaier K,Gutierrez A

OPA1-03083 was used in Western Blotting to test the hypothesis that asparaginase-resistant leukemia cells harbor gain-of-fitness alterations whose therapeutic targeting would be uniquely toxic to tumor cells upon treatment with the enzyme.

Mon Apr 15 00:00:00 UTC 2019

Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.

Science translational medicine

Wagner FF,Benajiba L,Campbell AJ,Weïwer M,Sacher JR,Gale JP,Ross L,Puissant A,Alexe G,Conway A,Back M,Pikman Y,Galinsky I,DeAngelo DJ,Stone RM,Kaya T,Shi X,Robers MB,Machleidt T,Wilkinson J,Hermine O,Kung A,Stein AJ,Lakshminarasimhan D,Hemann MT,Scolnick E,Zhang YL,Pan JQ,Stegmaier K,Holson EB

OPA1-03083 was used in Western Blotting to demonstrate feasibility of paralog-selective GSK3α inhibition, offering a promising therapeutic approach in AML.

Wed Mar 07 00:00:00 UTC 2018

Silver nanoparticles induce neurotoxicity in a human embryonic stem cell-derived neuron and astrocyte network.

Nanotoxicology

Repar N,Li H,Aguilar JS,Li QQ,Drobne D,Hong Y

OPA1-03083 was used in Western Blotting to study the neurotoxicity that is induced by citrate-coated silver nanoparticles.

Thu Mar 01 00:00:00 UTC 2018

The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.

The Journal of clinical investigation

Banerji V,Frumm SM,Ross KN,Li LS,Schinzel AC,Hahn CK,Kakoza RM,Chow KT,Ross L,Alexe G,Tolliday N,Inguilizian H,Galinsky I,Stone RM,DeAngelo DJ,Roti G,Aster JC,Hahn WC,Kung AL,Stegmaier K

OPA1-03083 was used in western blot to study the potential of GSK3-alpha as a therapeutic target in human acute myeloid leukemia using a combination of genetic and small molecule screens

Thu Mar 01 00:00:00 UTC 2012

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more